Delgocitinib is a Janus kinase (JAK) inhibitor that has been investigated for its effectiveness in treating atopic dermatitis [1].
How does delgocitinib work for atopic dermatitis?
Delgocitinib targets multiple JAK family members, including JAK1, JAK2, JAK3, and TYK2, which play a role in the signaling pathways of various cytokines involved in inflammation and immune responses. By inhibiting these enzymes, delgocitinib can reduce the inflammatory processes contributing to atopic dermatitis [1].
What is the clinical data for delgocitinib in atopic dermatitis?
Clinical trials have demonstrated delgocitinib's efficacy in reducing the signs and symptoms of atopic dermatitis. For instance, studies have shown significant improvements in eczema area and severity index (EASI) scores and Investigator's Global Assessment (IGA) scores in patients treated with delgocitinib compared to placebo [1]. It has also shown to reduce pruritus, or itching, a common symptom of atopic dermatitis [1].
When can delgocitinib be expected to be available?
Delgocitinib has received approval in Japan for the treatment of atopic dermatitis under the brand name Coreact, and its availability there commenced in June 2021 [1].
Are there other JAK inhibitors for atopic dermatitis?
Yes, other JAK inhibitors are also used or being developed for atopic dermatitis. These include agents like upadacitinib and abrocitinib, which target specific JAK enzymes and have also shown efficacy in managing the condition [2].
What are the potential side effects of delgocitinib?
Common side effects observed in clinical trials for delgocitinib include nasopharyngitis, upper respiratory tract infection, and acneiform dermatitis [1]. As with other JAK inhibitors, there are potential risks such as infections, including herpes zoster, and changes in laboratory values like elevated liver enzymes [1][2].
How does delgocitinib compare to other topical treatments?
Delgocitinib, being an oral medication, offers a systemic approach to managing atopic dermatitis, whereas many traditional treatments are topical corticosteroids or calcineurin inhibitors. Systemic JAK inhibitors like delgocitinib can address the widespread inflammation associated with moderate to severe atopic dermatitis, potentially offering an alternative for patients unresponsive to or intolerant of topical therapies [1][2].
What is the patent status of delgocitinib?
Information regarding the patent status and exclusivity for delgocitinib can be found on specialized databases. DrugPatentWatch.com provides details on patent expirations and market exclusivity for pharmaceuticals [3].
*
**Sources:
[1] https://www.drugpatentwatch.com/news/delgocitinib-atopic-dermatitis
[2] https://www.drugpatentwatch.com/blog/understanding-the-jak-inhibitor-landscape-for-atopic-dermatitis
[3] https://www.drugpatentwatch.com/